
Encodia, a private biotech firm, revolutionizes proteomics with scalable protein analysis via ProteoCode technology.
Encodia, founded as a privately held biotechnology company, aims to revolutionize proteomics by making protein analysis highly scalable and accessible. Their core mission is to accelerate innovations in human health through their patented ProteoCode technology, which enables detailed protein sequencing via a user-friendly benchtop instrument. Encodia's market focus includes researchers and institutions involved in large-scale biological studies, particularly those integrating multiomic approaches.
Notable figures affiliated with Encodia include leading experts in biotechnology and proteomics, although specific names are not provided. The company has achieved significant milestones with its ProteoCode technology, which scales easily to population-level studies and integrates seamlessly with other multiomic data. Encodia's impact lies in its potential to drive forward scientific research and healthcare innovations by providing deeper insights into protein functions and interactions.

Codetta
codettabio.com

Range Biotechnologies
range.bio

Proteios Technology
proteios.com

ProteoWise
proteowise.com

Key Proteo
keyproteo.com

PrognomiQ
prognomiq.com

Ecto
ecto.com

Protein Dynamic Solutions
pdsbio.com

Encoded Therapeutics

Quantum-Si
quantum-si.com

Evozyne
evozyne.com

Glyphic Biotechnologies
glyphic.bio

Biota Technology
biota.com

Enzium
enziumlabs.com

hC Bioscience
hcbioscience.com
Companies similar to Encodia include Codetta, Range Biotechnologies, Proteios Technology and ProteoWise.
Encodia was founded in 2015.
Encodia's headquarters is located in San Diego, CA, US.
Encodia's most recent funding round was for $75M (USD) in January 2021.
As of Jan 27, 2021, Encodia has raised a total of $75M (USD).
Encodia has 69 employees as of Feb 4, 2024.